Indaptus Therapeutics (INDP) Projected to Post Earnings on Monday

Indaptus Therapeutics (NASDAQ:INDP) will likely be posting its quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Indaptus Therapeutics to post earnings of ($0.36) per share for the quarter.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($8.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($11.48) by $2.52. On average, analysts expect Indaptus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Indaptus Therapeutics Price Performance

Shares of NASDAQ:INDP opened at $7.17 on Friday. Indaptus Therapeutics has a fifty-two week low of $6.65 and a fifty-two week high of $58.24. The business has a 50-day moving average of $10.11 and a two-hundred day moving average of $15.05. The stock has a market capitalization of $4.09 million, a P/E ratio of -0.17 and a beta of 1.14.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.